Phospho-EGFR (S695) Antibody

What is the Phospho-EGFR (S695) Antibody and what is its primary research application?

Phospho-EGFR (S695) Antibody is a polyclonal antibody specifically designed to detect EGFR (Epidermal Growth Factor Receptor) phosphorylated at the serine 695 residue. The antibody is synthesized using peptides derived from human EGFR around the phosphorylation site of S695. This antibody serves as a critical tool for investigating EGFR signaling pathways in which S695 phosphorylation plays a regulatory role .

Primary research applications include:

• Western blotting (recommended dilution 1:500-1:2000)

• ELISA (recommended dilution 1:40000)

• Studying EGFR phosphorylation events in signal transduction cascades

• Investigating post-translational modifications in cancer research models

The antibody shows cross-reactivity with human, mouse, and rat samples, making it versatile for comparative studies across different model systems .

How does S695 phosphorylation compare with other EGFR phosphorylation sites in research significance?

While tyrosine phosphorylation sites like Y845 and Y1068 have been extensively characterized in EGFR signaling, S695 represents a serine phosphorylation site that may indicate distinct regulatory mechanisms:

Unlike the well-documented Y845 phosphorylation (which occurs in the activation segment of the kinase domain and promotes interaction with signaling molecules like STAT3 and CoxII), the specific functional consequences of S695 phosphorylation require further elucidation through targeted research approaches .

What are the optimal sample preparation methods when using Phospho-EGFR (S695) Antibody for Western blotting?

For optimal results in phospho-specific Western blotting using Phospho-EGFR (S695) Antibody:

• Cell Lysis Protocol:

  • Use ice-cold lysis buffer containing phosphatase inhibitors (e.g., sodium orthovanadate, sodium fluoride, β-glycerophosphate)

  • Include protease inhibitors to prevent protein degradation

  • Maintain low temperature throughout sample processing to preserve phosphorylation

• Sample Handling:

  • Process samples quickly to minimize dephosphorylation

  • Use fresh samples when possible; if freezing is necessary, snap-freeze in liquid nitrogen

  • Avoid repeated freeze-thaw cycles that can affect phosphorylation status

• Controls:

  • Include both phosphorylation-induced (e.g., EGF-treated cells) and non-induced samples

  • Consider including samples treated with phosphatase inhibitors versus phosphatase-treated samples

  • A293-EGF cells have been successfully used as positive controls

• Gel Conditions:

  • Use 7-8% gels for optimal resolution of high molecular weight EGFR (~175 kDa)

  • Transfer to membrane using standard protocols for large proteins (longer transfer times may be necessary)

These methodological considerations are essential for preserving the phosphorylation state and generating reliable data on S695 phosphorylation status .

How can I validate the specificity of Phospho-EGFR (S695) Antibody in my experimental system?

Validating antibody specificity is crucial for phospho-specific detection. Implement these approaches:

• Phosphatase Treatment:

  • Treat duplicate samples with lambda phosphatase to remove phosphorylation

  • The phospho-specific signal should disappear in phosphatase-treated samples while total EGFR remains detectable

• Stimulation/Inhibition Studies:

  • Compare untreated versus EGF-stimulated cells (25 ng/mL for 5 minutes has been effective for EGFR phosphorylation studies)

  • Include samples treated with relevant kinase inhibitors

  • Analyze using both Western blot and ELISA methods to confirm consistency of results

• Peptide Competition:

  • Pre-incubate antibody with synthetic phosphopeptide containing the S695 phosphorylation site

  • This should abolish specific binding in Western blot or immunostaining

  • Use non-phosphorylated peptide as a control

• EGFR Knockdown/Knockout Controls:

  • Compare EGFR-expressing cells with EGFR-depleted cells

  • The S695 phospho-specific signal should be absent in EGFR-depleted samples

• Orthogonal Detection Methods:

  • Confirm phosphorylation using mass spectrometry-based approaches

  • Compare results with other commercially available antibodies if possible

These validation steps help ensure that the observed signals truly represent S695 phosphorylation rather than cross-reactivity with other phosphorylation sites or proteins.

How can Phospho-EGFR (S695) Antibody be used to investigate the relationship between EGFR mutations and therapeutic resistance in cancer?

EGFR mutations are frequently associated with cancer progression and therapeutic resistance. Phospho-EGFR (S695) Antibody can be utilized in sophisticated research designs:

• Mutation-Specific Phosphorylation Profiling:

  • Compare S695 phosphorylation patterns across cell lines harboring different EGFR mutations (e.g., L858R, T790M as seen in non-small-cell lung cancer)

  • Correlate S695 phosphorylation status with response to EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib or erlotinib

  • Investigate whether S695 phosphorylation serves as a biomarker for TKI sensitivity or resistance

• Signaling Pathway Analysis:

  • Perform parallel analysis of multiple phosphorylation sites (Y845, Y1068, S695) to develop comprehensive phosphorylation signatures

  • Use phosphoproteomic approaches to identify proteins that interact specifically with S695-phosphorylated EGFR

  • Investigate whether S695 phosphorylation influences downstream signaling through PI3K/AKT or RAS/MAPK pathways

• Therapeutic Intervention Studies:

  • Monitor changes in S695 phosphorylation after treatment with various targeted therapies

  • Investigate whether combination therapies (e.g., EGFR TKIs plus Src inhibitors) differentially affect S695 versus tyrosine phosphorylation

  • Determine if S695 phosphorylation status predicts clinical outcomes in patient-derived samples

This research approach may reveal whether S695 phosphorylation represents a novel therapeutic target or resistance mechanism in EGFR-driven cancers.

What methodological approaches can be used to investigate the kinases responsible for S695 phosphorylation of EGFR?

Identifying the kinase(s) responsible for S695 phosphorylation requires sophisticated biochemical and molecular approaches:

• Kinase Inhibitor Screening:

  • Systematically treat cells with inhibitors targeting different kinase families (e.g., PKC, PKA, CDK, MAPK)

  • Monitor S695 phosphorylation status after inhibitor treatment using the Phospho-EGFR (S695) Antibody

  • Correlate inhibition patterns with known kinase selectivity profiles

• In Vitro Kinase Assays:

  • Express and purify the EGFR kinase domain or a peptide containing the S695 region

  • Screen a panel of purified kinases for their ability to phosphorylate S695 in vitro

  • Confirm phosphorylation by mass spectrometry and immunoblotting with Phospho-EGFR (S695) Antibody

• Genetic Approaches:

  • Perform CRISPR-Cas9 or siRNA-mediated knockdown of candidate kinases

  • Overexpress constitutively active or dominant-negative kinase mutants

  • Assess changes in S695 phosphorylation through quantitative Western blotting

  • Combine with phosphoproteomic analysis to identify co-regulated phosphorylation sites

• Structural Biology:

  • Use molecular modeling to predict kinases with substrate specificity matching the S695 sequence context

  • Compare with known regulatory phosphorylation sites in other receptor tyrosine kinases

  • Design S695 phosphomimetic (S695D/E) and phospho-deficient (S695A) mutants to study functional consequences

These approaches would significantly advance our understanding of EGFR regulation beyond the well-characterized tyrosine phosphorylation events .

What strategies can address weak or inconsistent signals when using Phospho-EGFR (S695) Antibody in Western blotting?

When encountering weak or variable signals with Phospho-EGFR (S695) Antibody, consider these methodological solutions:

• Phosphorylation Preservation:

  • Ensure complete phosphatase inhibition during sample preparation

  • Use freshly prepared buffers with appropriate inhibitor cocktails

  • Maintain samples at 4°C throughout processing

  • Consider using phosphatase inhibitor combinations targeting different phosphatase classes

• Antibody Optimization:

  • Titrate antibody concentration beyond recommended ranges (1:250-1:3000)

  • Extend primary antibody incubation time (overnight at 4°C may improve signal)

  • Test different blocking agents (BSA vs. milk protein; BSA is generally preferred for phospho-detection)

  • Optimize secondary antibody selection and concentration

• Signal Enhancement Strategies:

  • Consider using enhanced chemiluminescence (ECL) substrates with higher sensitivity

  • Explore signal amplification systems (e.g., biotin-streptavidin systems)

  • Increase protein loading (up to 100 μg per lane may be necessary for low-abundance phosphorylation)

  • Use PVDF rather than nitrocellulose membranes for potentially better protein retention

• Sample Enrichment:

  • Consider immunoprecipitating total EGFR first, then probing for S695 phosphorylation

  • Use phospho-enrichment techniques (e.g., TiO2 chromatography) prior to Western blotting

  • Compare results with ELISA-based detection which may offer improved sensitivity

These technical optimizations can significantly improve detection of S695 phosphorylation, especially in systems with low baseline phosphorylation levels.

How can potential cross-reactivity issues with other phosphorylated residues be addressed when using Phospho-EGFR (S695) Antibody?

Cross-reactivity is a common concern with phospho-specific antibodies. Implement these approaches to ensure specificity:

• Epitope Mapping and Blocker Experiments:

  • Use synthetic phosphopeptides containing S695 and similar phosphorylation sites

  • Perform competition experiments with these peptides

  • Include blocking experiments with peptides containing other EGFR phosphorylation sites (especially those near S695)

• Mutant EGFR Controls:

  • Generate S695A mutant EGFR expression constructs

  • Compare antibody reactivity between wild-type and S695A mutant samples

  • Include other serine-to-alanine mutations as controls

• Mass Spectrometry Validation:

  • Confirm phosphorylation site identification by LC-MS/MS analysis

  • Use targeted methods like selected reaction monitoring (SRM) for absolute quantification

  • Compare with phospho-antibody detection to validate specificity

• Dual Detection Methods:

  • Use an antibody against total EGFR on the same samples

  • Calculate phosphorylation/total protein ratios for more reliable quantification

  • Employ multiple detection methods (Western blot, ELISA, immunofluorescence) to cross-validate results

These rigorous validation approaches are essential for confident interpretation of data generated using phospho-specific antibodies in complex biological systems.

How might S695 phosphorylation interact with tyrosine phosphorylation events to regulate EGFR function and signaling?

Understanding the interplay between serine/threonine and tyrosine phosphorylation represents an advanced research frontier:

• Hierarchical Phosphorylation Analysis:

  • Design time-course experiments to determine if S695 phosphorylation precedes or follows tyrosine phosphorylation events

  • Use site-specific phospho-antibodies to monitor multiple phosphorylation sites simultaneously

  • Analyze whether S695 phosphorylation affects the kinetics or extent of tyrosine phosphorylation at sites like Y845 or Y1068

• Conformational Impact Assessment:

  • Investigate whether S695 phosphorylation alters EGFR kinase domain conformation

  • Determine if S695 phosphorylation affects the accessibility of the activation segment containing Y845

  • Use structural approaches (e.g., hydrogen-deuterium exchange mass spectrometry) to detect conformational changes

• Signaling Pathway Interactions:

  • Examine whether S695 phosphorylation modulates Src binding to EGFR

  • Investigate possible crosstalk with PKC-dependent regulation of EGFR

  • Analyze the effect of S695 phosphorylation on EGFR dimerization and endocytosis

• Functional Consequences:

  • Compare cellular responses (proliferation, migration, survival) in cells expressing wild-type versus S695 phosphorylation-site mutants

  • Investigate whether S695 phosphorylation alters sensitivity to different EGFR ligands

  • Determine if S695 phosphorylation influences EGFR localization or trafficking

These investigations may reveal novel regulatory mechanisms governing this critical receptor tyrosine kinase in normal and pathological states.

What role might S695 phosphorylation play in EGFR transactivation by heterologous stimuli?

EGFR transactivation by G-protein coupled receptors (GPCRs), integrins, and other stimuli represents a complex signaling mechanism that may involve S695 phosphorylation:

• Transactivation Pathway Mapping:

  • Monitor S695 phosphorylation after stimulating cells with GPCR agonists, cytokines, or integrin ligands

  • Compare with EGF-induced direct activation

  • Determine if S695 phosphorylation occurs during stress-induced EGFR activation (e.g., UV, osmotic stress)

• Signaling Intermediates Identification:

  • Investigate the role of PKC isoforms, which are known to regulate EGFR through T654 phosphorylation

  • Determine if Src-family kinases, implicated in Y845 phosphorylation, also influence S695 phosphorylation

  • Explore potential connections with calcium signaling pathways

• Functional Impact Analysis:

  • Compare endocytic trafficking of EGFR after direct activation versus transactivation

  • Investigate whether S695 phosphorylation differentially affects signaling outcomes in these contexts

  • Determine if S695 phosphorylation influences the duration or compartmentalization of EGFR signaling

• Therapeutic Implications:

  • Evaluate whether targeting pathways that regulate S695 phosphorylation could provide alternative approaches to modulating EGFR signaling

  • Compare the effects of EGFR tyrosine kinase inhibitors on different phosphorylation sites during transactivation

  • Investigate potential for combination therapies targeting both canonical and non-canonical EGFR activation

These studies would address fundamental questions about receptor crosstalk mechanisms and potentially identify novel therapeutic approaches for EGFR-dependent diseases.

What quantitative approaches should be used when analyzing Western blot data generated with Phospho-EGFR (S695) Antibody?

Rigorous quantification is essential for meaningful interpretation of phosphorylation data:

• Normalization Strategies:

  • Always normalize phospho-EGFR (S695) signals to total EGFR levels

  • Include loading controls (β-actin, GAPDH) as secondary normalization

  • Consider using stain-free technology for total protein normalization

  • Calculate and report phospho/total EGFR ratios rather than absolute phospho-signal

• Statistical Analysis Requirements:

  • Perform at least three independent biological replicates

  • Apply appropriate statistical tests (ANOVA with post-hoc tests for multiple comparisons)

  • Report both mean values and measures of variability (standard deviation or standard error)

  • Use non-parametric tests if normality assumptions are violated

• Dynamic Range Considerations:

  • Ensure signals fall within the linear range of detection

  • Generate standard curves using positive control samples at different dilutions

  • Avoid overexposure that can mask differences between experimental conditions

  • Consider using fluorescent rather than chemiluminescent detection for improved linearity

• Complementary Approaches:

  • Validate key findings using ELISA-based quantification

  • Consider mass spectrometry-based approaches for absolute quantification

  • Compare results with phospho-flow cytometry if studying cell populations with potential heterogeneity

These quantitative approaches enhance the reliability and reproducibility of phosphorylation research and facilitate meaningful comparisons across experimental conditions and studies.

How should discrepancies between Western blot and ELISA results using Phospho-EGFR (S695) Antibody be interpreted and resolved?

When facing discordant results between detection methods:

• Fundamental Method Differences:

  • Western blotting detects denatured proteins while ELISA measures native conformation

  • ELISA may detect epitopes masked by protein-protein interactions in cell lysates

  • Western blotting provides molecular weight confirmation while ELISA may be more sensitive

• Systematic Troubleshooting Approach:

  • Validate antibody specificity in both formats using phosphopeptide competition

  • Test different lysis conditions that may affect epitope accessibility

  • Compare results using different antibody concentrations and incubation conditions

  • Consider developing a sandwich ELISA using total EGFR capture and phospho-S695 detection

• Experimental Design Adaptations:

  • Include positive controls (EGF-stimulated cells) and negative controls (phosphatase-treated samples)

  • Perform parallel analysis with antibodies against other EGFR phosphorylation sites

  • Test different sample preparation methods that may preserve phosphorylation differentially

  • Consider the timing of sample collection relative to stimulation

• Interpretation Framework:

  • If methods consistently disagree, report both results and discuss possible explanations

  • Consider whether different subcellular fractions or EGFR populations are being detected

  • Evaluate whether post-translational modifications beyond phosphorylation affect epitope recognition

  • Use orthogonal methods (mass spectrometry) as a third approach when critical results depend on accurate quantification

This systematic approach allows researchers to resolve technical discrepancies and extract meaningful biological insights despite methodological limitations.

What emerging technologies might enhance the detection and functional characterization of EGFR S695 phosphorylation?

Advanced technologies are expanding our capabilities for studying phosphorylation events:

• Proximity Ligation Assays (PLA):

  • Enable in situ detection of phosphorylation in fixed cells and tissues

  • Allow simultaneous detection of S695 phosphorylation and protein-protein interactions

  • Provide single-molecule sensitivity and subcellular localization information

• CRISPR-Based Approaches:

  • Generate endogenously tagged EGFR variants for live-cell imaging

  • Create precise S695 phosphorylation site mutants in relevant cell types

  • Develop cellular reporters of S695 phosphorylation status

• Single-Cell Phosphoproteomics:

  • Analyze heterogeneity in S695 phosphorylation across cell populations

  • Correlate with other signaling events at single-cell resolution

  • Integrate with spatial information through imaging mass cytometry

• Phospho-Specific Nanobodies and Intrabodies:

  • Develop high-affinity, single-domain antibodies against phospho-S695

  • Express intracellularly to track phosphorylation in living cells

  • Combine with optogenetic approaches for spatiotemporal manipulation

• Synthetic Biology Approaches:

  • Engineer phosphorylation-dependent protein switches based on S695 phosphorylation

  • Develop cellular circuits that respond specifically to S695 phosphorylation status

  • Create biosensors that allow real-time monitoring of phosphorylation dynamics

These emerging technologies promise to transform our understanding of EGFR phosphorylation events and their functional consequences in both normal and disease states.

How might computational approaches contribute to understanding the structural and functional significance of S695 phosphorylation?

Computational methods offer powerful tools for investigating phosphorylation events:

• Molecular Dynamics Simulations:

  • Model the structural consequences of S695 phosphorylation on EGFR conformation

  • Simulate interactions between phospho-S695 and potential binding partners

  • Predict allosteric effects on the EGFR kinase domain

• Systems Biology Modeling:

  • Integrate S695 phosphorylation into comprehensive models of EGFR signaling networks

  • Predict the impact of S695 phosphorylation on signal duration, amplitude, and downstream pathway activation

  • Model potential feedback and feedforward loops involving S695 phosphorylation

• Machine Learning Applications:

  • Analyze proteomics datasets to identify patterns correlating with S695 phosphorylation status

  • Develop predictive models for S695 phosphorylation based on cellular context and stimuli

  • Mine cancer genomics data to identify correlations between S695 phosphorylation and clinical outcomes

• Evolutionary Analysis:

  • Compare conservation of S695 and surrounding sequences across species

  • Identify co-evolving residues that may interact with phospho-S695

  • Relate evolutionary patterns to functional significance in different cellular contexts

These computational approaches complement experimental methods and can generate testable hypotheses about the structural and functional significance of S695 phosphorylation in diverse biological contexts.

What is the potential significance of EGFR S695 phosphorylation as a biomarker in cancer research?

Exploring S695 phosphorylation as a cancer biomarker requires systematic investigation:

• Clinical Correlation Studies:

  • Analyze S695 phosphorylation patterns across tumor types and stages

  • Compare with established EGFR biomarkers (mutation status, expression level, Y1068 phosphorylation)

  • Correlate S695 phosphorylation with patient outcomes and treatment responses

  • Evaluate potential as a complementary biomarker to existing EGFR diagnostics

• Methodological Standardization:

  • Develop immunohistochemistry protocols using Phospho-EGFR (S695) Antibody on formalin-fixed paraffin-embedded tissues

  • Establish scoring systems for quantifying S695 phosphorylation in patient samples

  • Create reference standards for inter-laboratory comparison

  • Validate using multiple detection methods including mass spectrometry

• Therapeutic Response Prediction:

  • Investigate whether S695 phosphorylation status predicts response to EGFR-targeted therapies

  • Determine if changes in S695 phosphorylation during treatment correlate with outcomes

  • Explore potential as an early marker of acquired resistance mechanisms

• Integration with Other Biomarkers:

  • Analyze the relationship between S695 phosphorylation and other cancer biomarkers

  • Develop multiparameter models incorporating S695 phosphorylation with other molecular features

  • Investigate potential for inclusion in comprehensive phosphoproteomic tumor profiling

These translational research approaches could establish whether S695 phosphorylation offers unique diagnostic, prognostic, or predictive value in cancer management.

How might understanding EGFR S695 phosphorylation contribute to developing novel therapeutic strategies?

Exploiting knowledge of S695 phosphorylation may open new therapeutic avenues:

• Targeted Drug Development:

  • Design small molecules that specifically block S695 phosphorylation

  • Develop peptide mimetics that compete with regulatory proteins for binding to phospho-S695

  • Engineer antibody-drug conjugates that specifically target cells with elevated S695 phosphorylation

• Combination Therapy Strategies:

  • Investigate whether modulating S695 phosphorylation enhances response to existing EGFR inhibitors

  • Identify synthetic lethal interactions involving S695 phosphorylation status

  • Develop rational drug combinations targeting both S695-dependent and -independent pathways

• Resistance Mechanism Insights:

  • Determine if altered S695 phosphorylation contributes to resistance to EGFR tyrosine kinase inhibitors

  • Investigate whether targeting kinases responsible for S695 phosphorylation could overcome resistance

  • Explore dynamic changes in S695 phosphorylation during treatment and disease progression

• Patient Stratification Approaches:

  • Use S695 phosphorylation status to identify patient subgroups likely to benefit from specific therapies

  • Develop companion diagnostics based on S695 phosphorylation for clinical trials

  • Implement precision medicine approaches incorporating S695 phosphorylation data

These therapeutic applications highlight the potential translational impact of basic research on EGFR S695 phosphorylation in addressing unmet medical needs in EGFR-driven diseases.